Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 1998

View Archived Issues

YM-175: a new-generation bisphosphonate with antihypercalcemic activity

Omnicare to acquire Ibah

Attenuation of septic insult with a combination of ibuprofen, cimetidine and diphenhydramine

NaPro BioTherapeutics reports stabilizing formulations of paclitaxel

Overview of preclinical and clinical data for rHuMGDF

BEHAB: a new target for the treatment of glioma

H. pylori infection and the pathogenesis of gastric disorders

OSI Pharmaceuticals and Hoechst Marion Roussel extend EPO collaboration

Gilead reports preliminary results from Preveon trials for the treatment of HIV infection

Adefovir dipivoxil shows promise in the treatment of hepatitis B

Famciclovir shows better activity than valaciclovir in preclinical trials for the treatment of HSV

Carter-Wallace discontinues sepsis study

John Wayne Cancer Institute begins phase III trials of melanoma cancer vaccine

ProCyte receives FDA clearance for wound dressing

Tamoxifen trial for breast cancer prevention produces surprisingly positive results

Vaccine against pneumococcal disease shown safe and immunogenic in children

Adenosine antagonists for CNS, cardiovascular and other disorders

Erythromycins for Gram-positive and other infections in development at HMR

Bisplatinum complexes with potent antitumor activity revealed

World's first NDA filing for an antisense drug

Radical-scavenging furan nitrone compounds in the pipeline at Centaur

FDA advisory committee will meet to discuss Ergoset NDA

Orphan Medical receives approval to market Sucraid in U.S.

Molecular Biosystems, Chugai establish agreement for imaging agents

Novartis presents new tyrosine kinase inhibitor with antiresorptive activity

Atrix receives approvable letter from FDA for Atridox

Taisho's rugatocenones inhibit cell adhesion

Novel ECE inhibitor isolated from Streptomyces

FDA approves fifth indication for Neupogen

New bFGF-TK inhibitor from Parke-Davis

Antiangiogenic ribozyme from Ribozyme and Chiron presented at cancer meeting

Antitumor combretastatin A4 derivative reported by Ajinomoto